apremilast (Otezla) - Articles and news items

NICE says ‘no’ to apremilast for psoriatic arthritis

Industry news / 3 September 2015 / Victoria White

NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis…


Celgene’s Otezla® (Apremilast) receives European Marketing Authorisation

Industry news / 19 January 2015 / Celgene

An oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements…

Celgene Logo

Celgene receives positive CHMP opinion for OTEZLA® (apremilast)

Industry news / 24 November 2014 / Celgene International Sàrl

Celgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis…

Celgene Logo

Oral apremilast significantly improved nail and scalp psoriasis and health-related quality of life measures in phase III esteem 1 study

Industry news / 3 October 2013 / Celgene

Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...